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Abstract
The current COVID-19 pandemic is affecting different countries in different ways. The assortment of reporting techniques alongside
other issues, such as underreporting and budgetary constraints, makes predicting the spread and lethality of the virus a challenging
task. This work attempts to gain a better understanding of how COVID-19 will affect one of the least studied countries, namely
Brazil. Currently, several Brazilian states are in a state of lock-down. However, there is political pressure for this type of measures
to be lifted. This work considers the impact that such a termination would have on how the virus evolves locally. This was done
by extending the SEIR model with an on / off strategy. Given the simplicity of SEIR we also attempted to gain more insight by
developing a neural regressor. We chose to employ features that current clinical studies have pinpointed has having a connection to
the lethality of COVID-19. We discuss how this data can be processed in order to obtain a robust assessment.
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1. Introduction
The Coronavirus Disease 2019, whose aetiological agent is
known as Severe Acute Respiratory Syndrome Coronavirus 2
(SARS-CoV-2) [1], has been dubbed COVID-19 by the World
Health Organization (WHO). The virus has been spreading
worldwide and was effectively classified as a pandemic by the
WHO [2]. The first cases were reported to the chinese bureau
of WHO in December 2019 in Wuhan City, Hubei Province of
China [3]. Given that the pandemic is still quite recent, sev-
eral efforts are underway to try to predict its evolution, namely
in terms of spread, infection rates, mortality, amongst other di-
mensions [4, 5, 6, 7, 8].
However, by checking interactive web-based dashboards
(e.g., [9]) it has become clear that, globally, reporting methods
appear to differ substantially from country to country. Possible
factors for such divergences may include lack of testing facili-
ties, monetary constraints, geographical scale, under-reporting
and even political unwillingness to divulge the true scale. Given
the reliability issues related to the reported data, there is no con-
sensus over the mortality rates associated to COVID-19 (e.g.,
[10]). For example, while [11] argues that the rates are overes-
timated, [12] argue otherwise. Consequently, some have started
to question whether the COVID-19 epidemic can be managed
on the basis of daily data [13].
Understandably, most of the studies have focused on the con-
tagion scenarios in Europe and China. To our knowledge, there
appears to be a lack of COVID-19 related research focusing
on south America, more specifically Brazil, home of approx-
imately 211 million people, the world’s fifth-largest country
by area and currently the world’s 8th largest economy. Brazil-
specific predictions incorporating government introduced mit-
igation strategies were made available in [14] for the states of
S£o Paulo and Rio de Janeiro. These represent the two largest
economic units of the union and also concentrate a significant
part of the population. However, the true local scale is difficult
to assess. In part, this is due to under-reporting of cases owing
to chronic tests shortages [15]. Furthermore, the official fig-
ures only include deaths reported by hospitals. A more detailed
analysis of current research is presented in Section 2.
The set of guiding questions behind this work can be stated
as follows: It is common knowledge that political leadership
in Brazil has at times conveyed contradictory messages on how
best to tackle the crisis. Some argue for the necessity of mit-
igation measures, whilst others defend that these will result in
insurmountable damage to the economy. As a result, can public
trust in civil servants affect the epidemic? Given the current set
of Brazilian public policies aiming at mitigation, how will this
affect the local spread of COVID-19? What would be the ef-
fects of more relaxed non-pharmaceutical measures? Section 3
exploits these questions by proposing a carefully designed quar-
antine strategies based on the availability of hospitalisation beds
and evaluating these strategies in time by means of a traditional
SEIR epidemic model.
Furthermore, is it possible to predict how COVID-19 will
affect Brazil based on what is happening in other countries?
What features should be considered? Are there any peculiarities
to Brazil? E.g. How is Brazil different from high-contagion
scenarios such as Europe and the USA? How does the quality of
the Brazilian health system affect the epidemic? Finally, given
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what we know so far about the underlying clinical conditions
affecting mortality rate, how does Brazil fare? We attempt to
provide an answer to these questions in Section 4 by employing
publicly-available data alongside a neural regressor. The main
conclusions of this work are presented in Section 5.
2. Related Work
COVID-19’s human-to-human transmission is via droplets or
by direct contact with an infected person [16]. An early es-
timate of the epidemic size in Wuhan, China, was presented
in [17]. The forecast was based on the number of cases ex-
ported to international destinations. Several incubation peri-
ods have been cited in the literature, namely, 5.2 days [18] to
6.4 days [19]. Furthermore, estimates of the basic reproduc-
tion number R0, a measure describing the average number of
secondary cases resulting from an infected person, also vary
widely. For example, the intervals [2.243.58] and [1.43.8] ap-
pear in [16] and [20], respectively.
Currently, there are multiple ongoing clinical trials world-
wide to assess the effectiveness and safety of certain drugs such
as chloroquine, arbidol, remdesivir, and favipiravir [21]. In
vitro data has suggested that chloroquine inhibits virus replica-
tion [22], although clinical testing has failed to provide such a
strong case so far. Also, clinical studies suggest the apparent ef-
ficacy of chloroquine phosphate in the treatment of pneumonia
following COVID-19 infection [23]. However, as [24] carefully
points out there is a delicate margin between a therapeutic and
a toxic dose. The study reinforces the need for further trials to
help validate the claims and design future guidelines.
Given the current lack of proven pharmaceutical solutions,
most governments around the world have pursued public poli-
cies promoting social distancing, e.g.: closures of schools and
universities, remote work when possible, travel restrictions,
public gatherings bans, amongst other measures. Additional
measures hinge on early detection and isolation, contact trac-
ing, and the use of personal protective equipment [20]. These
measures have been referred to as non-pharmaceutical interven-
tions and a number of studies have been performed in order to
assess the effectiveness of these strategies.
Perhaps some of the best known scientific reports coming out
are the COVID-19 series produced by Imperial College. One
of these is [4], which then projected 510,000 deaths in Great
Britain and 2.2 million in the United States of America, in the
case of an unmitigated epidemic. The authors also projected
that even if all patients then these numbers would be revised
down to, respectively 250,000 deaths and 1.1-1.2 million. The
authors also draw attention to the fact that there is a lag between
the introduction of mitigation and the corresponding decrease in
hospitalization cases. At the time, their work also strongly em-
phasized that even for their most optimistic scenario, the num-
ber of sick people would far outstrip the available hospital ca-
pacity.
Subsequently, [5] presented estimation of the number of in-
fections and the impact of non-pharmaceutical interventions.
This was done by using a semi-mechanistic Bayesian hierarchi-
cal model to attempt to infer the impact on 11 european coun-
tries. One of their key findings is that the decrease in the num-
ber of daily deaths being reported from Italy is in accordance
with a significant impact from strict measures introduced weeks
beforehand. The authors estimate that (i) between 7 and 43 mil-
lion individuals, 1.88% and 11.43% of the population, to have
been infected up to March, 28th; and that (ii) 59,000 deaths had
been averted through non-pharmaceutical interventions.
In [6] the authors analyse different mortality scenarios, from
the absence of mitigation measures to policies designed to sup-
press transmission. They estimate: (i) 7.0 billion infections and
40 million deaths without mitigation; (ii) 4.5 billion infections
and 20 millions deaths with mitigation strategies focused on
protecting elderly groups and preserving social distancing; (iii)
that healthcare systems would be unable to cope even in the lat-
ter scenario. Consequently, the work strongly emphasizes the
need for public health measures leading to a reduction in trans-
mission rates, in order to avoid the collapse of global health
systems.
A recent study proposed a fairly detailed dynamic model to
describe the virus spread in China [7]. A drawback is that the
model requires 12 parameters that are approximated from real-
world data. We argue that such an approximation may lead to
highly unreliable estimates given the poor quality and the relia-
bility issues connected to the data made available. Regardless,
their main findings, namely that R0 quickly decreases with con-
tainment measures and that short quarantines do not suffice to
stop the epidemics, hold true and do not depend on the quality
of the data.
A simpler SIR (susceptible-infected-recovered) model was
applied to data from the UK and Italy [8]. The study suggests
that (i) the epidemics originated at least a month before the first
reported death and (ii) that two to three months of control mea-
sures would halt the epidemic. Although the former finding
has been used to justify herd immunity strategies, that is hardly
in keeping with the reported mortality rates worldwide. To il-
lustrate the point, let us assume a mortality rate of 1% in the
UK. Then, the reported figure of 167 deaths per million as of
April 14 (e.g., worldometers.info), would suggest the contagion
of approximately 1.67% of the population. Hence, while the
models are useful to guide decision, a holistic and exhaustive
analysis is needed to avoid biased assessments.
A model-based analysis aimed at trying to predict mortal-
ity rates was described in [25]. The authors were able to pro-
duce age-stratified estimates of the infection fatality ratio. Their
findings also estimated the mean duration from symptoms on-
set to fatality to be 17.8 days, whilst time from symptoms to
discharge was calculated as 24.7 days. The overall fatality rate
was estimated at 1.38%. However, older age groups were more
afflicted. Fatality increased to 6.4% among individuals aged 60
or older and reached 13.4% of those aged 80 or older.
A study compiled and analyzed data from 1099 Chinese pa-
tients with confirmed diagnose of COVID-19 [26]. Patients
most at risk of: (i) being admitted to an intensive care unit; (ii)
requiring ventilator; or (iii) death included people aged 60 or
older and also those with coexisting disorders such chronic ob-
structive pulmonary disease, diabetes, hypertension, coronary
heart disease, cerebrovascular conditions, hepatitis B, cancer,
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chronic renal disease and compromised immune systems. Some
authors have also attempted to correlate mortality rates to the
Bacillus Calmette-Gurin (BCG) childhood vaccination against
tuberculosis [27]. The authors found a positive significant cor-
relation between the establishment of universal BCG vaccina-
tion and mortality rate.
3. SEIR Model with on/off Strategy
Following the trend in the literature [e.g., 4, 5], we used the
classical compartmental SEIR (susceptible, exposed, infected,
removed) model to describe the virus spread. We argue that,
given the uncertainty in the data, a simple but interpretable
model can be more useful to provide insights for decision mak-
ing. The proposed model considers a mean incubation period
of 7 days [19] and a mean time to outcome (recovery or death)
of 21 days, in line with [25]. We use SEIR instead of the
simpler SIR model [8] because, in contrast to the latter, it in-
cludes the incubation period and allows us to replicate the de-
layed response to interventions in the system. To model the
same spread, [28] employed a more detailed approach, whilst
[8] made use of a simplified SIR model.
In order to capture the long-term behaviour, we simulated the
system for a period of two years. Figure 1 depicts the dynam-
ics. Notice the steep increase in the infected population, char-
acteristic of the pandemic. Observe also that the proportion of
infected individuals peaks around 50% of the population, which
would overload any health system in the world.
Figure 1: SEIR dynamics for Brazil.
The Brazilian health system has experienced a period of de-
creased investment and counts with around 2 hospital beds per
thousand citizens [29]. To protect this system, some states in
the federation are enforcing a lock-down strategy, albeit some-
times challenged by the federal government. This paper pro-
poses a parametric on-off strategy whereby lock-down would
be enforced when the number of hospitalisations due to the epi-
demic approaches the total number of hospital beds, and re-
moved when the occupation recedes to a lower threshold. For
the sake of simulation, we assume a hospitalisation rate of 10%
[e.g., 25]. Hence, the lock-down and and relaxation thresholds
can be alternatively set in terms of the total total number of
infected patients. Our simulations do not consider the devel-
opment of curative medication or of an effective vaccine in a
two-year horizon. Naturally, should any of these developments
occur, the control strategies would have to be completely refor-
mulated.
The first strategy is reported in Figure 2 and corresponds to
activating lock-down whenever the number of infections over-
comes 1.5% of the population, which corresponds to an occu-
pation of 1.5 beds per thousand inhabitants (75% of the beds).
Conversely, the lock-down is relaxed when the bed occupation
reaches 25%, or infection decreases below 0.5% of the popu-
lation. Notice that after two years, nearly 40% of the popula-
tion will have been infected and therefore be possibly immune.
When one considers the results later described in Section 4, this
also means the death of around one to three percent of the pop-
ulation (2.5% to 7.8% of the infected population).
Figure 2: SEIR dynamics for 25% and 75% thresholds.
Figure 3 details the evolution of the infected and exposed
populations. Observe that, even though the control policy is
set for a 1.5% threshold, the number of infected individuals ex-
ceeds 2% in the peaks because exposed individuals become in-
fected after the onset of the lock-down. Moreover, the peaks
decrease over time, as the susceptible population goes down.
Notice also that the lock-down periods alternate with compara-
tively small relaxation intervals.
Figure 3: SEIR dynamics for 25% and 75% thresholds.
Figure 4 depicts the populations for a 50%-100% strategy.
Lock-down is enforced when hospital beds are full and relaxed
when less than half are occupied. With respect to the 25%-
75% policy, we observe an increase in the infected population,
with about 60% of the population being infected after two years.
This is due to the increased occupation in the health system.
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Unfortunately, in view of the results of that will be presented
Section 4, the result implies the death of 1.5% to 4.6% of the
population.
Figure 4: SEIR dynamics for 50% and 100% thresholds.
However, as detailed in Fig. 5, the number of required beds
is in excess of 3 per thousand inhabitants in the early peaks, sig-
naling that a significant expansion of the health system would
be needed. Another insight of the simulations is that the relax-
ations have to be carefully studied and the thresholds carefully
calibrated in order to avoid the collapse of the health system.
Figure 5: SEIR dynamics for 50% and 100% thresholds.
4. Neural Prediction of the Brazilian Case Fatality Rate
The death toll due to COVID-19 in different scenarios is
one of the most important quantities to forecast. It can be in-
ferred from the number of infected individuals when the overall
case fatality rate (CFR) is known. Unfortunately, the reported
Brazilian CFR is not reliable, due in part to insufficient test-
ing [15]. Bearing that in mind, we propose a model to predict
the Brazilian CFR based on information acquired from COVID-
19 data repositories worldwide.
The proposed model utilizes a committee of neural predic-
tors, each with the architecture depicted in Fig. 6. The com-
mittee is able to combine individual weak predictors in order to
produce an improved overall regression [30]. Given the varia-
tion of the data, and considering the reliability issues surround-
ing multiple data sources, we use the median of the weak pre-
dictors to hedge against outliers [30, 31]. Fig. 7 illustrates the
committee strategy.
Input
Data
Normalization Features Extraction
Neural PredictorEstimated CFR
Figure 6: Block diagram of the architecture of a single neural predictor (i.e., a
single model).
Model #1
...
Model #N
Model Selection Prediction Committee
Combination StepConfidence interval for the CFR
Figure 7: Block diagram of the proposed committee machine. Note that the
combination step is the median operator, and that the confidence interval can
be computed using variability statistics derived from the “Model Selection”
procedure.
Note that the CFR strongly depends on several risk factors,
which can be related to either individual or societal features.
Among the former, one finds chronic medical conditions (espe-
cially diabetes [32], cardio-cerebrovascular diseases [33], hy-
pertension [34] and respiratory system diseases [1]), pregnancy
[35], obesity [36] and advanced age [34]. We can argue that
social factors that influence the CFR have attracted less atten-
tion, although their impact cannot be dismissed as negligible.
Among these factors, one may emphasize: shortage of medical
protection in developing countries [37], risk perception by the
community [38], political commitment to allocate resources in
order to reduce disaster risks [39], disaster risk governance [40],
appropriate allocation of humanitarian response and develop-
ment activity [41], participatory approaches that change risk
management [42], and institutional differences [43]. It is a chal-
lenging task to incorporate such factors in a regression model,
mainly due to the absence of reliable metrics for the major-
ity of countries that have experienced COVID-19 dissemina-
tion. Fortunately, there are some quantitative features available
for the countries of interest that are correlated with the afore-
mentioned factors (e.g., it is expected that the indicator “En-
forcement of regulations”, provided by the Legatum Institute, is
correlated with institutional differences between different coun-
tries). Overall, a total of ten features were selected, which are
detailed in Table 1. These features are the inputs to the neural
predictors. Since some countries that present a small number
of confirmed COVID-19 cases often have distorted CFRs, the
analysis has excluded countries whose number of COVID-19
cases (i.e., variable x9) is lower than 200. After this pruning
procedure, 75 countries still remain, resulting in the following
matrix of input data X ∈ R10×75
X ,
[
x(1) x(2) . . . x(75)
]
, (1)
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Variable Indicator Source
x1 Obesity LT
x2 Smoking LT
x3 Healthcare coverage LT
x4 Raised blood pressure LT
x5 Public trust in politicians LT
x6 Enforcement of regulations LT
x7 Population over age 65 (%) WBDI
x8 Fatalities of cardiovascular diseases (%) WHO
x9 Number of COVID-19 cases WOI
x10 Number of COVID-19 fatalities WOI
Table 1: Input features utilized for the CFR neural regressor. Sources:
LT (Legatum Institute), WBDI (World Bank Development Indicators),
WHO (World Health Organization Global Estimates 2016), WOI (from
www.worldometers.info).
where x(k) ,
[
x1(k) x2(k) . . . x10(k)
]T
contains the met-
rics for the 10 features of the k-th country (see Tab. 1).
Since the available data is unrealiable, a careful data process-
ing should be performed to guarantee a robust CFR prediction
for the Brazilian case. The first processing procedure is exe-
cuted to enhance the neural network accuracy (and to speed up
training) by reducing the internal co-variate characteristics of
the data [44]. In this first step, each entry of the matrix X is
manipulated in order to obtain a normalized matrix X˜, whose
elements are computed as
x˜i, j =
xi, j − µˆi
σˆi
, (2)
where µˆi (resp. σˆi) is the average (resp. standard deviation)
of the i-th row of X. The chosen neural regressor is the logis-
tic feedforward neuron, whose output, for a set of adjustable
parameters wi,∀i ∈ {0, 1, . . . ,m − 1}, is described as
y( j) =
1
1 + exp
[
−w0 −∑m−1i=1 wi xˆi, j] , (3)
where xˆi, j is distinct from x˜i, j because of the feature extraction
procedure. This procedure is advisable due to lack of sufficient
training samples to enforce proper constraints in the neural net-
work parameters, so that the desired estimation is considered
a mathematical ill-posed problem [45]. It implies that over-
fitting issues should be mitigated. One tool used for this pur-
pose is the Principal Component Analysis (PCA), which aims to
obtain the most compact representation of a high-dimensional
data under the sense of least square reconstruction error [46].
Loosely speaking, it can be described as an unsupervised linear
dimensionality reduction technique that presents robust feature
extraction properties [46]. The number m of principal compo-
nents was selected by k-fold cross validation (a kind of model
selection technique), in which the data set instances are ran-
domly divided into k disjoint folds with approximately equal
size, and every fold is in turn used to test the model trained
from the other k − 1 folds [47]. Using k = 10 folds and training
the neural networks with the backpropagation algorithm under
the mean quadratic error cost function, the mean absolute error
(MAE) for each number of principal components is depicted in
Fig. 8.
Figure 8: Box-plot of the mean absolute error (MAE) obtained with different
number of principal components.
m Estimated CFR
3 0.0213
4 0.0255
5 0.0266
Table 2: The estimated Brazilian CFR with respect to the number of principal
components. The median estimated is presented in boldface.
Observe that architectures with three to five principal com-
ponents perform better. These are selected in our study and
provide the estimates in Table 2. Observe that the point-
wise estimate of the neural committee for the Brazilian CFR
is CFR = 0.0255. Due to data inaccuracies and to the large
differences in the estimated losses in human lives, the variabil-
ity of such an estimate should be taken into account. In this
context, it is more appropriate to adopt a prediction interval,
which depends on the variability of the estimator. Since such a
variability can be estimated by the k-fold cross-validation, one
may compute the upper bound CFRαup of a confidence interval
of α% [48]. Such an upper bound is CFR68.27up = 0.0548 (resp.
CFR95up = 0.0782) for a confidence interval of 68.27% (resp.
95%). The median prediction is in line with the official statis-
tics as of April 14 2020 (5.7% - www.worldometers.info). This
suggests that either (i) the underreporting in death cases is sim-
ilar to the underreporting in the overall cases, or (ii) the testing
and reporting biases are captured by the selected variables in
the model.
5. Conclusions
Given the wide assortment of afflictions currently plaguing
public available data over COVID-19, it is a challenging task
to make reliable predictions concerning the spread and lethality
of COVID-19. Consequently, data may be inaccurate and must
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be utilized with caution, which restricts the reliability of fore-
casting models constructed with them. It was already demon-
strated that an inaccurate confirmed-case data induces noniden-
tifiability in the model calibrations, which helps to explain the
wide range of forecasting variations [49]. For example, un-
derreporting mild cases implies a reduction on the mortality
rate [50, 38]. Unfortunately, such inconsistencies in reporting
COVID-19 cases are a serious problem, which might sabotage
the mitigation of its harmful effects and complicate the outbreak
response [51]. Additional uncertainties derive from the fact that
key characteristics of the transmissibility of COVID-19 (such as
whether its transmission can occur before symptom onset) are
currently unknown [52].
Yet, despite the apparent gaps in knowledge, it is still possi-
ble to gain invaluable insight. Namely, by combining the ex-
isting SEIR model with an on / off lock-down policies one can
see that the impact of the virus will be spread through multi-
ple waves of decreasing amplitude. Such a scenario would ef-
fectively mean that there would exist multiple waves requiring
flattening over time, in the absence of effective medication, an
appropriate vaccine of the development of herd immunity.
Current epidemiological models such as SEIR are also rela-
tively simple. As a result, we developed a neural regressor that
considers features that the current literature also deems as im-
portant factors in the lethality of COVID-19. This allows for
non-linear extrapolations. Again, the issue of data unreliability
surfaces. Through careful data processing alongside PCA and
k-fold cross validation we believe that it is possible to obtain a
more robust CFR prediction for Brazil.
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